Annual meeting moves to the New York Marriott Marquis on October 13-16, marking a new chapter and providing a refreshed ...

The NDA is supported by data from the EXCALIBER-RRMM trial, which evaluated the safety and efficacy of iberdomide, an investigational cereblon E3 ligase modulator.

A myeloma survivor in long remission shares how research, expert care and advocacy turned fear into hope as more patients ...

Jaime Suarez-Londono, MD: Transplant for myeloma is very easy to give. On day 12 they engraft and they go home. Adverse events are not that [severe], and they get this progression-free survival [PFS] ...

Iberdomide has the potential to be the first approved CELMoD agentThe U.S. FDA has granted Breakthrough Therapy Designation and Priority Review for this indication and assigned a target action date of ...

Renowned Hindi and Marathi actress Pravina Deshpande passed away at 60 after battling multiple myeloma since 2019. Known for Ghar Ek Mandir, Kumkum, and films like Ready, she faced skin eruptions, ...

After a broken femur led to a multiple myeloma diagnosis, one patient is raising awareness while specialists point to new treatment options and early detection.

Phase 3 trial results suggest daratumumab, which is approved for multiple myeloma, may also be effective at reducing relapse risk in neuromyelitis optica spectrum disorder.

Doctors at Boston’s Beth Israel share how CAR T cell therapy and other emerging immune therapies are delivering promising ...

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Q4 2025 Earnings Call Transcript February 12, 2026 Karyopharm Therapeutics Inc.

Genetically modified immune cells can offer precious additional time to patients with advanced multiple myeloma. However, these therapies lose their impact as the molecules on cancer cells that immune ...

Genetically modified immune cells can offer precious additional time to patients with advanced multiple myeloma. However, these therapies lose their impact as the molecules on cancer cells that immune ...